Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06115603 · ClinicalTrials.gov registry record · Phase 2
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
A Phase 2 study of Attention Deficit/Hyperactivity Disorder, sponsored by University of Arkansas, Fayetteville.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06115603 is a Phase 2 study of Attention Deficit/Hyperactivity Disorder that is actively recruiting participants, run by University of Arkansas, Fayetteville. The registered enrollment target is 76 participants, below the 294-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06115603, a Phase 2 study of Attention Deficit/Hyperactivity Disorder, is actively recruiting participants, sponsored by University of Arkansas, Fayetteville.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cannabigerol
Study Locations (1)
Arkansas
- University of Arkansas - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-12-14 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06115603
The ClinicalTrials.gov registry entry for NCT06115603 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 294-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (74% lower). The listed sponsor is University of Arkansas, Fayetteville, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06115603 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT06115603 about?
NCT06115603 is a clinical study titled "The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder". The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indic...
What is the current status of trial NCT06115603?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2024-12-14. Estimated completion is 2025-12.
What conditions does trial NCT06115603 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT06115603?
The interventions under investigation include: Placebo (OTHER), Cannabigerol (DRUG).
Who is sponsoring clinical trial NCT06115603?
This trial is sponsored by University of Arkansas, Fayetteville, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06115603 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Focus Groups in Ethnically and Racially Diverse Families
RECRUITING
-
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
RECRUITING · NA
-
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.